vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and Twin Hospitality Group Inc. (TWNP). Click either name above to swap in a different company.
Twin Hospitality Group Inc. is the larger business by last-quarter revenue ($82.3M vs $71.7M, roughly 1.1× Adaptive Biotechnologies Corp). Adaptive Biotechnologies Corp runs the higher net margin — -18.9% vs -29.7%, a 10.8% gap on every dollar of revenue. Adaptive Biotechnologies Corp produced more free cash flow last quarter ($1.4M vs $-7.4M).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Target Hospitality is a company that provides workforce lodging and other temporary, modular housing used for oil, gas and mining operations; large-scale events; and disaster relief. Target Hospitality is based in The Woodlands, Texas, and also has offices in Williston, North Dakota; Denver, Colorado; Calgary, Alberta.
ADPT vs TWNP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $82.3M |
| Net Profit | $-13.6M | $-24.5M |
| Gross Margin | 74.6% | — |
| Operating Margin | -17.8% | -16.2% |
| Net Margin | -18.9% | -29.7% |
| Revenue YoY | 51.0% | — |
| Net Profit YoY | 59.7% | — |
| EPS (diluted) | $-0.08 | $-0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | — | ||
| Q3 25 | $94.0M | $82.3M | ||
| Q2 25 | $58.9M | $87.8M | ||
| Q1 25 | $52.4M | $87.1M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $46.4M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $41.9M | — |
| Q4 25 | $-13.6M | — | ||
| Q3 25 | $9.5M | $-24.5M | ||
| Q2 25 | $-25.6M | $-20.8M | ||
| Q1 25 | $-29.9M | $-12.1M | ||
| Q4 24 | $-33.7M | — | ||
| Q3 24 | $-32.1M | — | ||
| Q2 24 | $-46.2M | — | ||
| Q1 24 | $-47.5M | — |
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
| Q4 25 | -17.8% | — | ||
| Q3 25 | 10.9% | -16.2% | ||
| Q2 25 | -42.5% | -13.2% | ||
| Q1 25 | -56.4% | -1.2% | ||
| Q4 24 | -71.3% | — | ||
| Q3 24 | -70.3% | — | ||
| Q2 24 | -109.6% | — | ||
| Q1 24 | -116.5% | — |
| Q4 25 | -18.9% | — | ||
| Q3 25 | 10.2% | -29.7% | ||
| Q2 25 | -43.5% | -23.7% | ||
| Q1 25 | -56.9% | -13.9% | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | — | ||
| Q2 24 | -107.0% | — | ||
| Q1 24 | -113.5% | — |
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.06 | $-0.43 | ||
| Q2 25 | $-0.17 | $-0.38 | ||
| Q1 25 | $-0.20 | $-0.26 | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.31 | — | ||
| Q1 24 | $-0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | — |
| Total DebtLower is stronger | — | $402.8M |
| Stockholders' EquityBook value | $218.8M | $-92.1M |
| Total Assets | $512.7M | $516.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | $43.2M | — | ||
| Q1 25 | $50.6M | — | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $38.1M | — | ||
| Q2 24 | $59.8M | — | ||
| Q1 24 | $71.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $402.8M | ||
| Q2 25 | — | $411.3M | ||
| Q1 25 | — | $413.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $218.8M | — | ||
| Q3 25 | $204.4M | $-92.1M | ||
| Q2 25 | $179.7M | $-78.6M | ||
| Q1 25 | $190.4M | $-101.9M | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | $223.8M | — | ||
| Q2 24 | $241.6M | — | ||
| Q1 24 | $274.9M | — |
| Q4 25 | $512.7M | — | ||
| Q3 25 | $490.6M | $516.8M | ||
| Q2 25 | $496.6M | $535.1M | ||
| Q1 25 | $510.9M | $544.2M | ||
| Q4 24 | $539.4M | — | ||
| Q3 24 | $558.5M | — | ||
| Q2 24 | $584.9M | — | ||
| Q1 24 | $620.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $-5.9M |
| Free Cash FlowOCF − Capex | $1.4M | $-7.4M |
| FCF MarginFCF / Revenue | 2.0% | -9.0% |
| Capex IntensityCapex / Revenue | 0.9% | 1.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | — | ||
| Q3 25 | $-7.1M | $-5.9M | ||
| Q2 25 | $-12.4M | $-8.8M | ||
| Q1 25 | $-28.5M | $-5.7M | ||
| Q4 24 | $-12.5M | — | ||
| Q3 24 | $-27.1M | — | ||
| Q2 24 | $-17.3M | — | ||
| Q1 24 | $-38.4M | — |
| Q4 25 | $1.4M | — | ||
| Q3 25 | $-7.5M | $-7.4M | ||
| Q2 25 | $-13.1M | $-10.6M | ||
| Q1 25 | $-29.7M | $-9.7M | ||
| Q4 24 | $-12.6M | — | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-39.9M | — |
| Q4 25 | 2.0% | — | ||
| Q3 25 | -8.0% | -9.0% | ||
| Q2 25 | -22.2% | -12.1% | ||
| Q1 25 | -56.7% | -11.2% | ||
| Q4 24 | -26.5% | — | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | — | ||
| Q1 24 | -95.2% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.4% | 1.9% | ||
| Q2 25 | 1.1% | 2.1% | ||
| Q1 25 | 2.4% | 4.6% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
TWNP
Segment breakdown not available.
